FOY 251|a metabolite of Camostat|CAS 71079-08-8

Cas No.:	71079-08-8
Chemical Name:	4-[[4-[(Aminoiminomethyl)amino]benzoyl]oxy]benzeneacetic Acid
Synonyms:	FOY251;FOY 251
SMILES:	N/C(=N/C1=CC=C(C(OC2=CC=C(CC(=O)[O-])C=C2)=O)C=C1)/N
Formula:	C₁₆H₁₄N₃O₄
M.Wt:	312.300063610077
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:	[1]. K Beckh, et al. Elimination of the Low-Molecular Weight Proteinase Inhibitor Camostate (FOY 305) and Its Degradation Products by the Rat Liver. Res Exp Med (Berl). 1987;187(6):401-6. [2]. Ai Maekawa, et al. Camostat Mesilate Inhibits Prostasin Activity and Reduces Blood Pressure and Renal Injury in Salt-Sensitive Hypertension. J Hypertens . 2009 Jan;27(1):181-9.

Description:	FOY 251 free base is an anti-proteolytic active metabolite camostate (HY-13512), acts as a proteinase inhibitor[1].
In Vitro:	FOY 251 free base represents a dose-dependent inhibition of equivalent current in M-1 cells[2]. FOY-251 free base inhibits the proteolytic activity of prostasin[2].
References:	[1]. K Beckh, et al. Elimination of the Low-Molecular Weight Proteinase Inhibitor Camostate (FOY 305) and Its Degradation Products by the Rat Liver. Res Exp Med (Berl). 1987;187(6):401-6.

Cat. No.	Product name	Field of application
DC39025	FOY-251	FOY 251 is a metabolite of Camostat and a pollen protease inhibitor for prevention and control of allergy.
DC39023	AT-511(Bemnifosbuvir free base)	AT-511, the free base form of AT-527, against several coronaviruses, including SARS-CoV-2, the causative agent of COVID-19. In normal human airway epithelial (HAE) cell preparations, the average concentration of AT-511 required to inhibit replication of S
DC31010	S-Hydroxychloroquine	S enantiomer of Hydroxychloroquine. Hydroxychloroquine is a potent drug for the COVID-19 trement.
DC31006	WP1122	WP-1122(WP 1122) is a candidate drug to treat SARS-COV-2(COVID-19) .2-DG completely prevented SARS-CoV–2 replication in Caco–2 cells. Glycolysis is a process by which cells convert glucose into energy and infected (host) cells are induced by viruses to dramatically increase their dependence on glycolysis. WP1122 is a prodrug of 2-DG whereby chemical elements are added to 2-DG to improve its delivery in vivo.
DC28041	BIOTIN-PEG4-SBP1(spike-binding peptide 1)	Biotin modification of SBP1.SBP1(spike-binding peptide 1) is a first-in-class peptide binder to the SARS-CoV-2 spike protein. SBP1 specifically binds SARS-CoV-2-RBD with low nanomolar affinity. SBP1 to the RBD was determined to be 47 nM with the average Kon = 4.69104M-1S-1 and Koff=2.210-3.The interaction between SBP1 and the RBD of SARS-CoV-2 spike protein was validated by bio-layer interferometry. The KD, derived from protein association and dissociation kinetics, was found to be 47 nM after averaging the fitting values at different protein concentrations. The amino acid sequence of SBP1 is entirely derived from human ACE2 and should be recognized as endogenous by the human immune system. This feature could be highly beneficial in later stages of pre-clinical development.
DC28040	SBP1(spike-binding peptide 1)	SBP1(spike-binding peptide 1) is a first-in-class peptide binder to the SARS-CoV-2 spike protein. SBP1 specifically binds SARS-CoV-2-RBD with low nanomolar affinity. SBP1 to the RBD was determined to be 47 nM with the average Kon = 4.69*104M-1S-1 and Koff
DC27035	EIDD-2801(Molnupiravir)	Molnupiravir, also known as EIDD-2801 and MK-4482, is an orally bioavailable form of a highly potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. EIDD-2801 has been show
DC27020	Arbidol analog	A Arbidol analog which showed affinity against both H3 (1150-fold) and H1 (98-fold) hemagglutinin subtypes than Arbidol.
DC21567	Triazavirin (Riamilovir)	Triazavirin is a guanine nucleotide analog antiviral originally developed in Russia that has shown efficacy against influenza A and B, including the H5N1 strain. It appears that Triazavirin has shown promise in reducing influenza disease severity and associated complications.5 Given the similarities between SARS-CoV-2 and H5N1, health officials are investigating Triazavirin as an option to combat SARS-CoV-2, the coronavirus responsible for COVID-19.
DC50035	PF00835231	PF00835231(SARS-CoV-2 inhibitor 5h) is areversible-covalent inhibitor of SARS-CoV-2 main protease (Mpro) with EC50 of 4.2 µM. Compound 5h blocks the infectivity and cytopathicity of the virus with high potency and without any detectable cytotoxicity even at 200 µM.PF-00835231 is a potent inhibitor of CoV-2 3CLpro with IC50 of 4 nM and shows suitable pharmaceutical properties to warrant further development as an intravenous treatment for COVID-19.

FOY-251